Genicity family is growing, and we are pleased to welcome Rainer Henning as our new CEO.
Rainer has more than 40 years experience in all aspects of drug discovery and development in pharma and biotech settings from target and lead discovery to regulatory approval; he has also worked successfully as a venture capital investor for several years.
His interests span cardiovascular, inflammatory and infectious diseases and their treatment with small-molecule drugs, peptides, recombinant proteins and advanced therapeutics.
He has a deep network in the pharma, biotech and venture capital industries. His previous managerial responsibilities include Deputy Head of Cardiovascular Research at Hoechst AG and Managing Director R&D for Nippon HMR (now part of Sanofi). His contributions were instrumental in the discovery and development of Hoechst's blockbuster ACE inhibitors Tritace and Odrik.
He was also CEO of clinical stage biopharmaceutical companies Fibrex Medical, Inc., Biomay AG and Viravaxx AG, as well as CSO of Worg Pharmaceuticals.
Rainer has a PhD in chemistry from Justus-Liebig-University in Giessen, Germany and 2 years of postdoctoral work at Colorado State University, Fort Collins, CO, USA.
Together with Rainer, Genicity will grow to become one of the leading global innovators in the field of allogeneic cell therapy.